Detouring of cisplatin to access mitochondrial genome for overcoming resistance - Wikidata - awgldk - TriplyDB

Detouring of cisplatin to access mitochondrial genome for overcoming resistance

Detouring of cisplatin to access mitochondrial genome for overcoming resistance

http://www.wikidata.org/entity/Q33972195

about

Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems.Targeting mitochondria metabolism for cancer therapy The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs Polymeric Nanostructures for Imaging and Therapy Metabolic interrogation as a tool to optimize chemotherapeutic regimens.The energy blocker inside the power house: Mitochondria targeted delivery of 3-bromopyruvate.Targeted nanoparticles in mitochondrial medicine.Mitochondria-Localized Fluorescent BODIPY-Platinum Conjugate.Histamine-functionalized copolymer micelles as a drug delivery system in 2D and 3D models of breast cancer.Microfluidic synthesis of rigid nanovesicles for hydrophilic reagents delivery A Highly Photostable Hyperbranched Polyglycerol-Based NIR Fluorescence Nanoplatform for Mitochondria-Specific Cell Imaging.ROS-Responsive Mitochondria-Targeting Blended Nanoparticles: Chemo- and Photodynamic Synergistic Therapy for Lung Cancer with On-Demand Drug Release upon Irradiation with a Single Light Source Polymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment.New formulation of old aspirin for better delivery Nanotechnology inspired tools for mitochondrial dysfunction related diseases.Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry.A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance.Nanoparticle formulations of cisplatin for cancer therapy.Platinum complexes as light promoted anticancer agents: a redefined strategy for controlled activation.Unique Use of Alkylation for Chemo-Redox Activity by a Pt(IV) Prodrug.Endoplasmic reticulum targeting tumour selective photocytotoxic oxovanadium(IV) complexes having vitamin-B6 and acridinyl moieties.Evaluation of nanoparticle delivered cisplatin in beagles.Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.The Platin-X series: activation, targeting, and delivery.Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.Integrating Enzymatic Self-Assembly and Mitochondria Targeting for Selectively Killing Cancer Cells without Acquired Drug Resistance.Mito-magneto: a tool for nanoparticle mediated mitochondria isolation.Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Novel mitochondria targeted copper(ii) complexes of ferrocenyl terpyridine and anticancer active 8-hydroxyquinolines showing remarkable cytotoxicity, DNA and protein binding affinity.Cisplatin induces mitochondrial deficits in Drosophila larval segmental nerve.Photoactive platinum(ii) β-diketonates as dual action anticancer agents.Mitochondrial selectivity and remarkable photocytotoxicity of a ferrocenyl neodymium(III) complex of terpyridine and curcumin in cancer cells.Off-Target Effects of Drugs that Disrupt Human Mitochondrial DNA Maintenance.Centrifugation-Free Magnetic Isolation of Functional Mitochondria Using Paramagnetic Iron Oxide Nanoparticles.The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats.An efficient two-photon fluorescent probe for monitoring mitochondrial singlet oxygen in tissues during photodynamic therapy.pH-Responsive de-PEGylated nanoparticles based on triphenylphosphine-quercetin self-assemblies for mitochondria-targeted cancer therapy.Redox-triggered activation of nanocarriers for mitochondria-targeting cancer chemotherapy.Targeting tumor glycolysis by a mitotropic agent.

P2860

Q26748776-3EBD2169-AEB1-4EEB-9ADA-527662A0FF74 Q27027219-E253FD22-06B8-4D62-A519-0A5970A99167 Q28066801-28D31492-5FA9-4269-AA09-A033A563211E Q30372383-1FCF6677-7992-4982-AC78-E7F20DCB02A3 Q33566853-B034E61B-4E83-43FA-BEA2-69E79B2F5EA0 Q35104357-B394F73F-42CB-4E5D-B3DA-822FCC773A12 Q35417165-9AB7D8FA-2982-4E75-AB63-1DC0242236EF Q35559785-EC936361-472C-47FF-8427-9C9B282AD670 Q35741040-84911CCA-938E-42FC-96D8-BE10EF2F02D2 Q35753701-A83A4273-2A6B-4546-AF0A-F3D917B7E774 Q36038123-AAFEBCBB-24D2-4650-8688-CC587B1456ED Q36201763-A4FB1679-EA04-4FBC-91EE-C6F7C688E21A Q36253687-3DA5D927-F308-4827-8A93-EA2F78C7B2F1 Q36373219-B2AD129F-A873-4CE1-B959-B0E6E3D21D58 Q36703351-2A1D251F-ECB0-44B9-8047-8A454C4BA01D Q38275908-574D1D2D-58CD-40C3-8840-35D6C225FEFB Q38720819-6456C91F-4C27-49FB-AD2E-3F80B50DDC09 Q38723829-694F6BA6-4532-49E3-A900-D436815795C5 Q38791247-1A0883A1-98B4-44ED-BF85-C3E90ADC434F Q38799693-53545636-3102-49F5-9D7E-7E06CAE5C393 Q38813722-54B35BA6-279F-42EB-85B5-E03BD2A31BC5 Q38847283-076C1C74-2E16-4BC6-98A1-4A22341A41B4 Q38868212-0934C670-D859-4BAE-8F19-E8D8B51862C8 Q38919253-23BE7C90-919E-4422-8A9C-0C45A1A23F8D Q38984857-F4656A03-671A-482B-AB88-3B04009C6075 Q39400621-28F49E42-79DA-462E-AB4D-6C836B385270 Q43237773-9BCBDF5E-9851-4C04-A02B-BDEB879C3BB0 Q45849106-F1155D38-9075-4393-B867-CFA272941746 Q46099008-31AE47C4-3023-4B10-BF36-95C43F9A07EC Q46449120-028A0F03-D6E6-482F-BBF3-FECC07C66A4D Q46472909-B2B6689D-2B3E-4303-B67C-880E0DB34093 Q46506519-06B13F5E-1AEF-4A2D-8D01-CFC676378035 Q46584322-7A2A7091-D38D-4C81-B8EC-D0BA3045991F Q47125109-EFA8BA3E-1470-4752-89EA-8C1D84D88F06 Q47786265-54B5C6AC-404F-4CDB-AB9B-02CC50BF272D Q48160138-471EBF1A-F320-4BAD-B642-121B227D5839 Q48312041-AE50A461-AFE2-4782-9372-507CF10F2238 Q48360842-71CB17E8-B187-4CB9-ACF8-EC65425CE329 Q48616806-9F4D35F0-BEC1-4F46-BE02-DC4CE21CFD15 Q50929846-6473369C-7C5C-4B50-8BC3-A30DEC077309

P2860

Detouring of cisplatin to access mitochondrial genome for overcoming resistance

http://www.wikidata.org/entity/Q33972195

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Detouring of cisplatin to access mitochondrial genome for overcoming resistance

@ast

Detouring of cisplatin to access mitochondrial genome for overcoming resistance

@en

type

label

Detouring of cisplatin to access mitochondrial genome for overcoming resistance

@ast

Detouring of cisplatin to access mitochondrial genome for overcoming resistance

@en

prefLabel

Detouring of cisplatin to access mitochondrial genome for overcoming resistance

@ast

Detouring of cisplatin to access mitochondrial genome for overcoming resistance

@en

P1433

Q33972195-E4577678-EE01-4225-B2F2-941BE9DA594D

P1476

Q33972195-1873B9D8-0A43-4398-B280-A96A3AFA4488

P2093

Q33972195-269C428A-3C88-4063-944B-734FD24E29CE

Q33972195-DC1155A1-2CB7-462E-89A9-F1C56BDE4647

Q33972195-F603B9D7-2397-4335-91B6-EB15652B5CD3

P2860

Q33972195-01BD660E-8E90-4842-8DD6-3FB2728AB560

Q33972195-05A3A1AB-2C20-4E75-BFF5-9E7C004BCE8F

Q33972195-10916665-3692-4127-8964-21DB25C544E7

Q33972195-2712EFE3-4B3D-4E72-9D23-7331918FE14C

Q33972195-385E2F1D-1096-4005-9590-1F4B72A82016

Q33972195-399F0D5F-8225-4483-9B5A-BE8C4670EDEF

Q33972195-3BF93FFA-5BB7-49C5-A650-9C051597392B

Q33972195-4F105683-6D6F-49DB-9758-1E61BD5586A6

Q33972195-5BDCC512-AEB7-4BD6-961E-9DAA91F054E6

Q33972195-8E40797C-B27E-4241-9177-DA63E1E2F55F

P304

Q33972195-4A227054-A375-4EA7-8B44-566F02AF4176

P31

Q33972195-C97F6A9F-4678-45F7-9ECE-94F71AF57B84

P356

Q33972195-5C9A008C-E319-483A-B94A-81297402A67D

P407

Q33972195-A5C76601-6519-491E-BB83-979718EE8FD0

P433

Q33972195-0AAAB88B-AD1C-431F-874E-5B90E32A3D79

P478

Q33972195-E16297D3-3DAA-45B1-B477-1986FCBDFD35

P577

Q33972195-9989FBD8-9C88-4576-B2AD-A90CDEB54FA0

P5875

Q33972195-F74B9E50-3555-4449-9109-49DF243CBA2E

P698

Q33972195-45A7BD94-074C-4E25-875B-3CAA3E5C4705

P932

Q33972195-7AF84223-AAF6-4F1F-A657-C6DB19282016

P356

PNAS.1405244111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Detouring of cisplatin to access mitochondrial genome for overcoming resistance

@en

P2093

Rakesh K Pathak

http://www.w3.org/2001/XMLSchema#string

Sean Marrache

http://www.w3.org/2001/XMLSchema#string

Shanta Dhar

http://www.w3.org/2001/XMLSchema#string

P2860

Nanocarriers as an emerging platform for cancer therapy

Molecular biology of neuroblastoma.

Targeting mitochondrial DNA with a platinum-based anticancer agent.

CNS delivery via adsorptive transcytosis.

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.

Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics

Copper-free click-chemistry platform to functionalize cisplatin prodrugs.

Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells.

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis

Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles

P304

10444-10449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1405244111

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263741884

http://www.w3.org/2001/XMLSchema#string

P698

25002500

http://www.w3.org/2001/XMLSchema#string

P932

4115573

http://www.w3.org/2001/XMLSchema#string